Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders

Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis.

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

May 18, 2017
Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress

May 1, 2017
Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results

March 29, 2017
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference

Read More News

Associated Team Members

Kevin Starr

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.

Glenn Pierce, M.D., Ph.D.